A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids

Trial Profile

A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Idebenone (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms SIDEROS
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 According to a Santhera Pharmaceuticals media release, information from this trial will be presented at the 113th American Thoracic Society (ATS) International Conference.
    • 24 Feb 2017 According to a Santhera Pharmaceuticals media release, the company anticipates that the trial will be fully enrolled by the end of 2017, and if successful the study will provide data that supports the use of idebenone in all DMD patients experiencing respiratory decline irrespective of their glucocorticoid use or genetic mutation.
    • 28 Sep 2016 According to a Santhera Pharmaceuticals media release, first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top